2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
9
Colorectal Neoplasms
7
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
4
Pancreatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Wilms Tumor
2
Urogenital Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplastic Syndromes, Hereditary
2
Neoplasms, Unknown Primary
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Kidney Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Interventions
Trastuzumab
33
pertuzumab
18
Docetaxel
16
pyrotinib
15
Paclitaxel
7
Capecitabine
6
tucatinib
5
Carboplatin
5
Ado-Trastuzumab Emtansine
4
trastuzumab deruxtecan
3
neratinib
3
atezolizumab
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
pegfilgrastim
1
palbociclib
1
margetuximab
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Hospital Information Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
Genetic Testing
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled